Problem: Menstrual disorders, reduced fertility and sexual problems seem to be more frequent in women with epilepsy than in the general population. Most investigations concerning menstrual disturbances in epilepsy patients, however, are small and based on selected materials. We therefore wanted to investigate the frequency of menstrual disturbances in a large, unselected population of epilepsy patients. Methods: A retrospective, questionnaire study of a cohort of female outpatients, aged 18-45 was conducted. Each patient chose a close female friend who served as control, to optimise matching regarding age and lifestyle. Results: Answers were received from 265 patients and 142 controls. Menstrual disturbances were more frequent in patients with epilepsy (48.0%) than in controls (30.7%) (P = 0.004). Menstrual disturbances were more frequent in patients on polytherapy versus monotherapy (P = 0.049) and more frequent in patients with high seizure frequency (>5 seizures/year) compared to patients with a lower seizure frequency or those seizure free (P = 0.006). The frequency of menstrual disturbances was higher in patients on valproate compared to carbamazepine monotherapy (P = 0.045).
INTRODUCTION
Several reports have demonstrated an increased frequency of menstrual disturbances, fertility problems, polycystic ovaries and hormonal changes in women with epilepsy [1] [2] [3] [4] [5] . This can be due to either the epilepsy itself, or the use of antiepileptic drugs (AEDs). In particular, epileptic activity in the temporal lobes seems to be related to endocrine effects 2, 6 . On the other hand, several AEDs are known to interfere with mechanisms involved in the regulation of the hypothalamic-pituitary axis 5, [10] [11] [12] , and AEDs may also affect the metabolism of steroid hormones and binding proteins 13 . Recently, valproate has been associated with the development of polycystic ovaries and hyperandrogenism in female epilepsy patients 11, 12, 14, 15 . These observations have been questioned by some authors, claiming that the studies were done in small and selected patient populations 16 .
An old investigation of healthy women without epilepsy showed menstrual disturbances in 27% 17 . In a study of normal women of reproductive age who had not sought treatment for menstrual disturbances, infertility or hirsutism, 18% were found to have irregular cycles 18 . Very few population-based studies on the frequency of menstrual disturbances in women with epilepsy have been performed, and those who exist are based on small and selected patient groups (ranging from 50 to 101 patients) without comparison with matched controls 3, 19 .
We wanted to investigate the frequency of menstrual disturbances in a larger group of female epilepsy out-patients and compare the results with those of a matched control population. We also wanted to study factors that might affect reproductive endocrine functions, such as seizure type and frequency, AEDs, age of epilepsy debut and body mass index (BMI).
METHODS
The study was retrospective and questionnaire-based. The intention was to investigate a non-selected group of epilepsy patients. The questionnaires were therefore sent to a cohort of 500 female out-patients recruited from three different Norwegian hospitals; Rikshospitalet, Ullevål University Hospital and Telemark Hospital. The patients were between 18 and 45 years of age. The questionnaire contained questions regarding the menstrual cycle, fertility, reproductive health, conception control and the epilepsy itself. Each patient received two questionnaires; one for themselves and one for a close friend without epilepsy. The friends served as a non-epileptic control group. This was done to optimise matching, regarding age and lifestyle. The study was approved by the Regional Ethical Committee. The epilepsy type was classified according to the classification system of the International League Against Epilepsy 20 . Menstrual disturbances were defined according to Polson et al. 18 , as periods of less than 22 days or more than 35 days, or bleeding duration of more than 8 days, or a variation of more than 4 days between two consecutive menstrual periods within the last 6 months.
Statistical analyses
The Chi-square test and Fisher's exact test were used for analyses of categorical data. Independent sample t-test was used for analyses of continues data. A value of P < 0.05 (two tailed) was considered significant.
RESULTS
Answers were received from 265 patients and 142 controls. Age, BMI and menarche age were equal between patients and controls ( Table 1 ). In the epilepsy group, 59.9% had partial and 35.9% generalised epilepsy. The epilepsy type could not be defined in 4.2% of the patients. 51.3% of the patients were seizure-free during the last 12 months, 15.5% had 1-5 seizures and 25.3% had more than 5 seizures during the last 12 months. 7.9% of the patients did not give sufficient information about seizure frequency. 60% were on monotherapy and 23.0% on polytherapy, while 13.6% did not use any medication (Table 1 ).
In the epilepsy group, 48.0% (94/196) had menstrual disturbances, compared to 30.7% (31/101) in the control group (P = 0.004) (Fig. 1) . In both groups, patients on contraceptive pills, using hormone IUD or who were pregnant were excluded from the analysis regarding menstrual irregularities.
Patients having more than 5 seizures during the last year had significantly more menstrual disturbances than seizure-free patients; 66% (31/47) compared to 38.9% (38/98) (P = 0.006) (Fig. 1) . There was no difference in frequency of menstrual disturbances between patients with primary generalised (50.7%) versus partial epilepsy (47.8%) (Fig. 2) .
In the monotherapy group, 45.1% (55/122) had menstrual disturbances compared to 62.2% (28/45) in the polytherapy group (P = 0.049) (Fig. 1) . Menstrual disturbances were significantly more frequent in all valproate treated patients (62%, n = 21) compared to all carbamazepine treated patients (37.2%, n = 59) (P = 0.045, Fig. 2 ). The frequency of menstrual disturbances was the same in patients using valproate for generalised epilepsy (63.6%, n = 11) compared to patients using valproate for partial epilepsy (55.5%, n = 9) (P = 0.67). The frequency of menstrual disturbances was also the same in patients using carbamazepine for generalised epilepsy (45.5%, n = 22) as in patients using carbamazepine for partial epilepsy (36.4%, n = 33) (P = 0.22) (Fig. 2) . Valproate treated patients had a higher frequency of menstrual disturbances than patients on all other drugs in monotherapy taken together, but this difference was not statistically significant (62% (n = 21) vs. 41.6% (n = 101); P = 0.072). Women with epilepsy had significantly fewer children than controls. Mean number of children per woman in the patient group was 0.85 versus 1.11 in the control group (P = 0.029) ( Table 1) .
There was no significant correlation between age of debut of epilepsy or how many years the patient had been suffering from epilepsy, and the frequency of menstrual disorders.
BMI was slightly higher in patients with menstrual disorders than in patients without menstrual problems (25.4 vs. 24.2), and in patients on polytherapy (25.9) compared to monotherapy (24.3), but the differences were not significant (P = 0.10 and 0.14, respectively). BMI in the valproate group (24.9) was higher than in patients treated with other drugs in monotherapy (23.9), but again the difference was not significant (P = 0.26).
A major problem with all retrospective, questionnaire-based studies is the responder rate, which was 53% in our study (265/500). We managed, however, to find 45 of the non-responders from one of the hospitals (Rikshospitalet). Medical records from these non-responders were reviewed and information analysed as for the patients ( Table 1 ). The only parameter that differed from the responders, was age of epilepsy debut that was about 3 years lower in the non-responder group.
DISCUSSION
This is the first population based study of menstrual disturbances in women with epilepsy where the results are compared to a matched control group of women without epilepsy. The main finding is that women with epilepsy experience a marked increase in menstrual disturbances. Thus, although menstrual disturbances are common in the general population 17, 18 , our study clearly emphasises the relation between epilepsy and menstrual disturbances. Our review of the medical records from non-responders did not reveal any major differences compared to women who answered the questionnaire. We therefore consider answers given in our study to be representative for women with epilepsy in our population in general.
The main question when trying to explain the increased frequency of menstrual disturbances in women with epilepsy, is whether this is caused by the epilepsy itself or by the treatment. Epileptic activity is shown to induce hormonal disturbances in both animals [7] [8] [9] and humans 2, 6, 21 . In our study, we found that women with more than 5 seizures during the last year had an increased risk of menstrual disturbances compared to seizure-free patients, while there was no difference between patients with partial versus generalised epilepsy. This implies that seizure frequency is more important than epilepsy type. However, the use of polytherapy was also significantly higher in patients with high seizure frequency (P < 0.001) and women on polytherapy had a higher frequency of menstrual disorders than women on monotherapy (P = 0.049). This makes it difficult to decide with certainty whether it is the epilepsy itself or the heavy medication that is of greatest importance for the development of the menstrual disorder.
The lack of difference in frequency of menstrual disturbances between women with partial compared to generalised epilepsy may be due to the fact that the different epilepsy types were treated differently. This does not seem to be the case. When looking at patients on valproate monotherapy, there was no difference regarding menstrual disturbances between those having partial or generalised epilepsy. Similar findings were done in carbamazepine treated women with no difference in menstrual disturbances in those treated for generalised or partial epilepsy. There were, however, significantly more menstrual problems among all women treated with valproate versus all women treated with carbamazepine. This indicates that the type of epilepsy is of less importance regarding development of menstrual disturbances.
Former studies 22 have shown an increased risk of anovulatory cycles in women with generalised epilepsy, particularly those on valproate. In the patients receiving phenobarbital and lamotrigine the epilepsy type had no significant effect. The seizure frequency was not taken into consideration in that study. In our study, seizure rate was a significant factor in increasing the frequency of menstrual disturbances. Other studies have shown increased frequency of endocrine dysfunction in patients with temporal lobe epilepsy. Because our study was a blinded questionnaire study we did not have enough detailed information to code the partial epilepsies into subgroups.
AED treatment has been found by several authors to induce menstrual disturbances 11, 12, 15, 23 . In our study, the relationship between polytherapy and menstrual disturbances was pronounced. We found that as many as 62.2% of patients on polytherapy had menstrual disturbances compared to 45.1% in the monotherapy group.
Type of medication has also been considered as having an effect on menstrual regularity. Previous studies have shown endocrine side-effects when using specific AEDs in monotherapy, especially valproate 11, 12, 14, 15, [23] [24] [25] . Our study supports these findings. We found that women using valproate in monotherapy are significantly more likely to have a menstrual disturbance than women taking carbamazepine irrespective of the epilepsy type, as discussed above. When comparing valproate to the group of all other AEDs in monotherapy, there was no significant difference in menstrual disturbances. The reason for this might be that lamotrigine is widely used in Norway, especially in women having menstrual disturbances. In our material, 13 of 21 patients using lamotrigine had menstrual disturbances. However, four of these women had changed medication from valproate to lamotrigine due to menstrual irregularities, and seven reported that the menstrual disturbances started before the use of AEDs. Thus, in only two patients menstrual disturbances started after the introduction of lamotrigine.
It has been claimed that the endocrine effects of valproate is caused by an increase in BMI 16 . In our study we found only a slightly higher BMI in patients treated with valproate than patients on all other drugs, but the difference was not significant. This weigh against BMI as a major factor in the development of menstrual disturbances in women treated with valproate.
In our study the epilepsy patients had fewer children than the control group (0.85 vs. 1.11, P < 0.05). The reason for this is complex. Seizure-free patients had significantly higher number of children than patients with more than 5 seizures a year (1.01 vs. 0.53 children, P = 0.001). Not having children can therefore be a deliberate choice in women with frequent seizures. For some of the women, epilepsy was only one symptom of a more complex neurological or medical disease. Some of these women have brain injuries or inherited diseases such as neurofibromatosis that makes pregnancies unfavourable. However, we can not rule out the possibility that reduced fertility could be due to epileptic activity itself as more seizures also were associated with a higher frequency of menstrual disturbances. Alternatively the use of AEDs inducing endocrine dysfunction could be responsible.
In conclusion, women with epilepsy have an increased frequency of menstrual disorders compared to women without epilepsy. Menstrual disturbances are significantly more frequent in women with high seizure frequency and in women on polytherapy. Menstrual disturbances are significantly more frequent in women on valproate compared to carbamazepine monotherapy. The reason for the increased risk for menstrual disturbances in women with epilepsy is complex, and probably caused by a combination of the epileptic activity and the antiepileptic medication.
